# Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children

> **NCT02377427** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 36 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Mepolizumab

## Key facts

- **NCT ID:** NCT02377427
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-25
- **Primary completion:** 2016-12-07
- **Final completion:** 2018-01-31
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02377427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02377427, "Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02377427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*